Formerly Ibrahim Medical College Journal
Affiliations: Department of Medical Oncology, University of Health Sciences, İzmir Tepecik Training and Research Hospital, İzmir, Turkey
Affiliations: Department of Hematology, University of Health Sciences, İzmir Tepecik Training and Research Hospital, İzmir, Turkey
Affiliations: Department of Internal Medicine, University of Health Sciences, İzmir Tepecik Training and Research Hospital, İzmir, Turkey
Background and objectives: Bone marrow metastasis (BMM) is a rare complication of solid tumors that carries a dismal prognosis. Readily applicable prognostic models for predicting survival in patients with BMM remain limited. This study aimed to identify prognostic factors affecting overall survival in solid tumor patients with BMM and to develop a clinically applicable prognostic risk score.
Materials and methods: Patients with solid tumors who developed BMM during follow up were retrospectively evaluated. Demographic characteristics, primary tumor features, metastatic disease status, hematologic and biochemical parameters, performance status, and antitumor treatments administered after BMM diagnosis were recorded. Overall survival (OS) was defined as the time from the diagnosis of BMM to death or the last follow up. Survival analyses were performed using the Kaplan–Meier method. Prognostic factors were evaluated using Cox proportional hazards regression analyses. A three tier prognostic risk score was established using the variables identified as independent prognostic factors in the multivariable analysis.
Results: A total of 58 patients were included in the study. OS following the diagnosis of BMM was notably poor. In multivariable analysis, de novo metastatic disease and the lack of antitumor therapy following BMM diagnosis were independently associated with inferior overall survival. Based on these two variables, the prognostic risk score stratified patients into low- (0 risk factors), intermediate- (1 risk factor), and high risk (2 risk factors) groups. The median overall survival was 7.8 months in the low risk group, 2.8 months in the intermediate risk group, and 0.5 months in the high risk group. A significant difference in OS was observed among the risk groups (log-rank p < 0.001).
Conclusion: In patients with BMM originating from solid tumors, de novo metastatic disease and the lack of antitumor therapy following BMM diagnosis were identified as independent poor prognostic factors. A simple prognostic risk score based on these two variables stratified patients into three distinct risk groups with markedly different survival outcomes. External validation studies in larger, independent cohorts are warranted to evaluate the model for clinical implementation.
July 2026; Vol. 20(2):007. DOI: https://doi.org/10.55010/imcjms.20.016
*Correspondence: Savas Gokcek, Department of Medical Oncology, University of Health Sciences, İzmir Tepecik Training and Research Hospital, Yenişehir, Konak, 35180, İzmir, Turkey Email:
© 2026 The Author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License(CC BY 4.0)